Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder

NCT05594121 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Moderate to Severe Opioid Use Disorder

Interventions

DRUG: Extended Release Subcutaneous Buprenorphine
DRUG: Immediate Release Sublingual Buprenorphine

Sponsor

Royal Victoria Hospital, Canada